Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd. develops cancer immunotherapy programs using its AI/ML-powered Unigen computational discovery capabilities to identify drug targets and biological pathways. News about CGEN commonly covers clinical and preclinical immuno-oncology programs, including COM701, COM902, rilvegostomig and GS-0321, as well as updates tied to immune-checkpoint targets such as PVRIG, TIGIT and IL-18 binding protein.
Recurring company developments include quarterly and annual financial results, corporate updates, scientific conference presentations, clinical data disclosures, partnership activity with AstraZeneca and Gilead, royalty and license arrangements, and board or leadership changes. Compugen's ordinary shares trade on Nasdaq and the Tel Aviv Stock Exchange under the ticker CGEN.
Compugen Ltd. (NASDAQ: CGEN) announced its participation in two upcoming virtual investor conferences. The first event is the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 16, 2020, at 9:30 AM ET. The second event is the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020, at 9:10 AM ET. Live webcasts of both presentations will be available on the Compugen website, with replays accessible afterward.
Compugen is focused on developing therapeutics in cancer immunotherapy, with lead candidates undergoing clinical trials.
Compugen Ltd. (NASDAQ: CGEN) announced the granting of a new patent by the USPTO for its immuno-oncology therapeutic antibody COM902, which targets TIGIT. The patent, U.S. Patent No. 10,751,415, secures the composition of matter for COM902, expiring no earlier than August 2037. This patent complements a previously issued patent covering its method of use in activating T cells, expanding intellectual property protection in the U.S. and Europe. COM902, currently in a Phase 1 trial, aims to enhance T cell function for patients with advanced malignancies.
Compugen Ltd. (Nasdaq: CGEN) reported its Q2 2020 financial results, highlighting advancements in cancer immunotherapy research. The company has initiated the Phase 1 monotherapy study of COM701 and is set to begin a triple combination study with its drugs, Opdivo®, and a TIGIT inhibitor by the end of 2020. Key findings include a 69% disease control rate in monotherapy and a 75% rate in combination therapy. Despite a net loss of $6.2 million, Compugen holds $136 million in cash, marking a significant increase from $44 million at the end of 2019.
Compugen Ltd. (Nasdaq: CGEN) will announce its second quarter 2020 financial results on July 30, 2020, prior to the U.S. market opening. Following the announcement, management will conduct a conference call at 8:30 AM ET to discuss the results and provide a corporate update. Investors can join the call via telephone or through a live webcast on Compugen's website. The company focuses on cancer immunotherapy, with lead candidates COM701 and COM902 currently in Phase 1 clinical studies.